X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/24/2869032/0/en/Freeline-to-Present-New-Data-on-its-Gaucher-and-Parkinson-s-Disease-Programs-at-the-American-Society-of-Gene-and-Cell-Therapy-ASGCT-27th-Annual-Meeting.html
https://www.globenewswire.com//news-release/2024/02/20/2831678/0/en/Acquisition-of-Freeline-by-Syncona-Becomes-Effective.html
https://www.globenewswire.com//news-release/2024/02/12/2827728/0/en/Freeline-Shareholders-Approve-Acquisition-by-Syncona.html
https://www.fiercebiotech.com/biotech/investment-firm-syncona-throws-lifeline-freeline-buying-out-struggling-biotech
https://www.globenewswire.com//news-release/2023/11/22/2784727/0/en/Syncona-to-Acquire-Freeline-Therapeutics.html
https://www.globenewswire.com//news-release/2023/10/25/2766204/0/en/Freeline-Presents-Positive-New-Data-from-Phase-1-2-GALILEO-1-Trial-of-FLT201-Its-Novel-Gene-Therapy-Candidate-in-Gaucher-Disease-at-ESGCT-30th-Annual-Congress.html
https://www.fiercebiotech.com/biotech/freeline-therapeutics-facing-fading-cash-runway-mulls-buyout-investor-syncona
https://endpts.com/syncona-eyes-buyout-of-gene-therapy-biotech-freeline-after-early-data-in-two-gaucher-patients/
https://www.globenewswire.com//news-release/2023/10/16/2760487/0/en/Freeline-to-Present-New-Clinical-Data-for-FLT201-in-Gaucher-Disease-in-Oral-Presentation-at-Upcoming-ESGCT-30th-Annual-Congress.html
https://www.globenewswire.com//news-release/2023/10/04/2754428/0/en/Freeline-Reports-Positive-Initial-Clinical-Data-from-First-Cohort-of-Phase-1-2-GALILEO-1-Trial-of-FLT201-Its-Novel-Gene-Therapy-Candidate-in-Gaucher-Disease.html
Market Place
Share 
